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West Nile (WN) virus is the cause of a potentially fatal
form of viral encephalitis that suddenly emerged in the New
York City area during 1999. The virus is a member of the
Flavivirus family, which includes St. Louis encephalitis
(SLE), Japanese encephalitis (JE), hepatitis C, and dengue
viruses (1,2). WN virus is common in West Asia, Africa, and
the Middle East but was not reported in the Americas until
the New York outbreak in 1999. The source of virus
introduction to New York City is unknown; potential sources
include an infected host (human or bird), an infected vector
(mosquito), or bioterrorism (1,3). The WN-NY99 virus
associated with the New York 1999 outbreak appears to have
been circulating in Israel since 1997 (1). Other close relatives
to the WN-NY99 virus were isolated in Italy (1998), Morocco
(1996), Romania (1996), and Africa (1989, 1993, and 1998).
Surveillance data indicate intensified transmission and
geographic expansion of the WN virus-NY99 outbreak in the
northeastern United States during 1999 and 2000. Twelve
states and the District of Columbia reported WN virus
activity in 2000, a substantial increase over the four states
reporting activity in 1999. WN-NY99 is expected to continue
to spread along the East Coast of the United States in 2001
and thereafter, as a result of overwintering of mosquitoes and
avian migratory patterns (4,5).
Virology
WN virus’s genome is 11,000 nucleotides long. The
following structural proteins have been identified: envelope
glycoprotein (env gp E), capsid (C), and premembrane protein
(prM). The following nonstructural proteins have also been
identified: NS-1, NS-2A/NS-2B, NS3, NS-4A/NS-4B; and NS-
5 (RNA-directed polymerase) (1). Isolates that have been
completely sequenced include the WN-NY99 virus originally
obtained from a Chilean flamingo, a WN-NY99 equine isolate,
the Italy 1998 virus, the Romania 1996 virus, and the
prototype Eg101 virus. Although the latter viruses are closely
related to WN-NY99, they are not identical to each other or to
WN-NY99 (6). A virus isolated in Israel, Israel 1998, appears
to be identical to WN-NY99; completion of its genome
sequence is under way at the Institute Pasteur, France.
Immunology and Immunopathogenesis
An extensive body of research is available on the
immunology of flaviviruses in the murine model; however,
relatively little research has been done on human immune
response to WN virus. Some information on human T-cell
responses to related viruses (e.g., JE virus, dengue) has been
obtained (7,8). Both CD4 T-helper cells and cytotoxic T-cells
that respond to JE virus and dengue proteins have been
identified, and their epitopes have been mapped (9). Some of
the JE virus CD4 T epitopes are identical or nearly identical
to sequences in WN virus (10). Langerhans cells in the
epidermis may play a role in the upregulation of immune
response to the virus, processing antigen and presenting it to
T cells (11,12). Mobilization of dendritic cells and antigen
presentation by these cells to T cells in the lymphoid follicles
may be involved in the development of immune responses to
WN virus (13).
Cytotoxic T-cell responses (restricted by class I major
histocompatibility complex [MHC] and MHC class II) and T
helper responses (restricted by class II MHC) appear to be
critical components of human immune response to members
of the flavivirus family (14,15). Cell-mediated immunity to
WN virus may prove to be an important barrier to infection of
the central nervous system, and vaccines that promote the
development of T-effector cells may provide protection from
WN virus encephalitis or may be used to treat patients who
have WN virus-related illnesses. Further research to test
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these hypotheses will require the development of reagents
such as the T-cell epitopes defined in this study.
Applying Bioinformatics to Defining T-Cell Epitopes
New bioinformatics tools developed by the TB/HIV
Research Lab and EpiVax (Providence, RI) enable researchers to
move rapidly from genome sequence to epitope selection (16).
EpiMatrix is a computer-driven pattern-matching algorithm
that identifies T-cell epitopes. BlastiMer permits the analysis
of protein sequences for homology with other known proteins.
The goal of this project was to demonstrate the utility of
a bioinformatics and computational immunology approach for
the rapid selection of T-cell epitope reagents. Defining these
reagents will permit the evaluation of cell-mediated
responses in the immunopathogenesis of WN virus, promote
the development of diagnostic reagents such as tetramers
(17), and provide components for epitope-based preventive or
therapeutic vaccines (18-20). A secondary goal was to
determine the time required to select and screen epitope
candidates in vitro, since time may be a critical factor in the
development of vaccines and diagnostic reagents in response
to emerging infectious pathogens.
On the basis of experience with the EpiMatrix HLA B*07
prediction tool, we selected peptides for this pilot study that
were expected to be restricted by HLA B*07. In studies of HIV-1
peptides, 60% of peptides selected by EpiMatrix HLA B*07
stimulated T-cell responses in vitro. We therefore expected that
approximately 60% of WN virus peptides selected by the same
criteria would bind to HLA B*07 and stimulate T-cell responses.
We screened 16 WN virus peptides and identified 12
epitope candidates, 5 of which exhibited strong binding to
HLA B*07 at a range of peptide concentrations in vitro. The
largest source of delay in the screening process was peptide
synthesis (4 weeks from placement of order to receipt of the
first set of peptides and 8 weeks until delivery of the final set
of peptides). This process could be accelerated if more rapid
access to MHC ligands were necessary.
The binding studies we describe are a first step to
confirming immunogenicity. In cases such as WN virus, in
which access to T cells from infected persons is limited, both
the bioinformatics step and the binding assays can be carried
out without clinical specimens. Once the epitope candidates
selected by this method are confirmed in cytotoxic T-cell
(CTL) assays, they may be useful for 1) screening exposed
persons for T-cell responses, 2) investigating the immuno-
pathogenesis of WN virus disease in humans, 3) as
components of diagnostic kits developed for WN virus
surveillance, 4) as reagents for measuring WN virus vaccine-
related immune responses, and possibly 5) as components of a
subunit vaccine for WN virus. Confirmation of T-cell response
to the peptides will depend on availability of peripheral blood
cells from WN virus-infected patients during the 2001
transmission season. Additional peptides also need to be
identified and screened for binding to other HLA alleles, to
broaden the MHC specificity of the diagnostic reagent or
immunopathogenesis tools developed by this approach.
Methods
Bioinformatics Analysis
We obtained the NY 1999 WN virus sequence from
GenBank (GenBank accession number AF196835) (21). The
3,433 amino acids in the GenBank translation were parsed
into 3,424 10-amino acid long frames, each 10 amino acid-long
peptide sequence overlapping the previous peptide sequence
by nine amino acids. The sequences of these 3,424 decamers
were stored in a database.
Each of the peptides in the database was then evaluated
by EpiMatrix, a matrix-based algorithm that ranks 9 and 10
amino acid peptides by estimated probability of binding to a
selected MHC molecule (22). The estimated binding potential
(EBP) is derived by comparing the EpiMatrix score with those
of known binders and presumed nonbinders. The EBP
describes the proportion of peptides with EpiMatrix scores as
high or higher than known binders for a given MHC molecule.
Both retrospective and prospective studies of EpiMatrix
predictions have confirmed the accuracy of this T-cell epitope
selection method (22-24). EpiMatrix is available for use by
HIV researchers on the TB/HIV Research Laboratory website
(http://tbhiv.biomed.brown.edu/) and under collaborative and
commercial arrangements with the TB/HIV Research
Laboratory and EpiVax, Inc. (Providence, RI), respectively.
Table 1 illustrates the process of selecting candidate
B*07 ligands from the WN virus genome. Of six overlapping
peptides in the region of the WN virus sequence shown (Table
1), WN virus B7 0019 scored in the same range as known B*07
ligands and HLA B*07-restricted epitopes (EBP 22.49).
Therefore, this peptide would be considered the most likely
candidate to show binding to HLA B*07 of the six peptides in
this illustration.
EBPs for the WN virus peptides ranged from >20%
(highly likely to bind) to <1% (very unlikely to bind) (Figure
1). We also scored 10,000 random peptides of natural amino
acid composition (25) derived from the ExPASy (Expert
Protein Analysis System) proteomics server at the Swiss
Institute of Bioinformatics (Randseq, http://www.expasy.ch/
tools/ randseq.html). We compared the HLA B*07 EpiMatrix
scores of this set of random peptides with those of a set of >300
known binders (compiled and maintained at EpiVax) and
with the scores of the set of WN virus peptides selected for this
study (Figure 2).
Selection of Peptides
Peptides with EpiMatrix EBP scores in the range of 7 to
50 are more likely to bind to MHC and stimulate T cells in
vitro (23). Peptides with an EBP score >50 are less likely to be
immunogenic, although they may bind to B7 in vitro (16,23).
Table 1. Scoring overlapping peptides by the EpiMatrix motif HLA B*07
   EpiMatrix analysis of West Nile virus protein NS-1
AA start Peptide no. (B*07 rank)    Sequence  EBPa
1123 WNB7 3119 GMEIRPQRHD   0.04
1124 WNB7 2818 MEIRPQRHDE   0.08
1125 WNB7 0591 EIRPQRHDEK   1.12
1126 WNB7 2660 IRPQRHDEKT   0.10
1127 WNB7 0019 RPQRHDEKTL 22.49
1128 WNB7 2661 PQRHDEKTLV   0.10
aEBP = estimated binding potential, which is the value that EpiMatrix uses to
describe the probability that the peptide will bind to B*07 in vitro and in vivo.
In this example, six overlapping peptides in the region of the WNV sequence
coding for the NS-1 protein (WNV genome AA 1123 to 1128) are shown.
WNVB7 0019 received the best EpiMatrix score (22.49) and was therefore
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Therefore, peptides scoring >50 in the WN virus set were
excluded. Based on these criteria, a final set of 22 peptides
with EBP scores from 20 to 50 (Table 2a, 2b) was selected for
screening in vitro. We excluded 3,329 WN virus peptides with
EBP scores <7, 70 potential B*07 binders with EBP scores >7
and <20, and 3 peptides with scores >50 (Table 2b).
Four of the lowest scoring WN virus peptides (EBP 0.00%,
Table 2a) were also selected to test the hypothesis that low
scoring peptides derived from WN virus would not bind to
HLA B*07 in vitro (predicted nonbinders). One well-defined
B*07-restricted epitope, GPGHKARVLA (derived from HIV),
was also chosen as a positive control for the assays (26).
Cross-Reactive Analysis
After the EpiMatrix analysis, the Conservatrix tool
(EpiVax, Providence, RI) was used to align and compare the
WN virus sequences with those of other related flaviviruses
(21). In an intermediate step designed to avoid selecting
epitopes that may have cross-reactivity with “self,” each of the
highly selected epitopes was passed through the Blast engine
at the National Center for Biotechnology Information, using
the BlastiMer tool (EpiVax, Providence, RI). Any sequence
that was similar to (i.e., >80% identical to the 10 amino acid
WN virus NY99 sequence) a peptide component of equivalent
length in the human genome (accessible and published to
date) was excluded from the study set.
Peptide Synthesis
Peptides corresponding to the epitope selections were
prepared by 9-fluoronylmethoxycarbonyl synthesis on an
automated Rainen Symphony/Protein Technologies synthe-
sizer (Synpep, Dublin, CA). The peptides were delivered 90%
pure as ascertained by high-performance liquid chromatogra-
phy, mass spectrophotometry, and UV scan. The peptides
were shipped as lyophilized powder, which was diluted in a
minimal volume of dimethyl sulfoxide and then diluted to
stock concentrations in RPMI 1640 medium (Sigma, St Louis,
Figure 1. Distribution of scores for the complete set of 3,424 peptides
obtained by parsing the West Nile (WN) virus genome into 10 amino-
acid long peptides, each overlapping by 9 amino acids, as scored on
the EpiMatrix motif for HLA B*07. Peptides with estimated binding
potential (EBP) scores >7 and <50 with the HLA B*07 motif are
highly likely to bind to HLA B*07 in T2 B7 assays and to stimulate T
cells. WN virus peptides with EBP scores between 20 and 50 were
considered for study.
Figure 2. EpiMatrix HLA B*07 score distributions for a random set of
10,000 peptides (dark blue), a set of 20 West Nile (WN) virus peptides
selected for screening (magenta), and a set of known HLA B*07
ligands (light blue) are compared. The natural log of estimated
binding potential (EBP) for all three sets (random, known binders,
and WN virus selections) fell within the range -5 to 5. Scores for the
set of WN virus peptides selected for this study are higher than those
of most random peptides and are within the same range as scores of
published HLA B*07 binders.
Tables 2. Selected West Nile virus peptides and their EpiMatrix scores
a. Peptides selected for screening in vitro
Peptide no.  AA
(B*07 rank) Source    Sequence start EBP
WNB7 0004 NS-1 AVKDELNTLL   861 48
WNB7 0005 mpM APAYSFNCLG   286 47
WNB7 0006 NS-2A AAKKKGASLL 1337 45
WNB7 0007 NS-2A NPMILAAGLI 1357 37
WNB7 0008 NS-3 IPAGFEPEML 1680 36
WNB7 0009 env gp E TPAAPSYTLK   460 36
WNB7 0010 NS-5 VPCRGQDELV 3259 33
WNB7 0011 NS-5 GPGHEEPQLV 2635 32
WNB7 0013 NS-5 EPPEGVKYVL 2895 31
WNB7 0015 NS-5 KPTGSASSLV 2842 29
WNB7 0017 NS-3 RPRWIDARVY 2098 24
WNB7 0018 NS-4A VPGTKIAGML 2223 23
WNB7 0019 NS-1 RPQRHDEKTL 1127 22
WNB7 0020 NS-3 SPHRVPNYNL 1777 22
WNB7 0023 NS-5 RPAADGRTVM 3112 21
WNB7 0024 NS-2A TPGLRCLNLD 1306 21
WNB7 3399 pre-mpM PEDIDCWCTK   185   0
WNB7 3403 NS-1 PETPQGLAKI   827   0
WNB7 3411 NS-3 PFPESNSPIS 1830   0
WNB7 3415 NS-5 PRTNTILEDN 2073   0
b. Peptides excluded from screening in vitro
Peptide no. Reason for  AA
(B*07 rank) not testing     Sequence start EBPa
WNB7 0001 EBP>50 RPSECCDTLL 2663 72
WNB7 0002 EBP>50 GPIRFVLALL     42 60
WNB7 0003 EBP>50 GPREFCVKVL 2703 55
WNB7 0012 Human-like AGMLLLSLLL 2229 31
WNB7 0014 Poor quality MPAILIALLV 1177 30
WNB7 0021 Poor quality IPMTIAGLMF 1405 22
WNB7 0025 Poor quality SVNMTSQVLL 2760 20
WNB7 0016 Not expressed IPTAAGKNLC   148 26
WNB7 0022 Not expressed MPRVLSLIGL     21 21
aEBP = estimated binding potential; env gp E = envelope glycoprotein E; prM =
pre-membrane protein; nonstructural proteins NS-1, NS-2A, NS-2B, NS-3,
NS-4A, NS-4B, and NS-5.709 Vol. 7, No. 4, July–August 2001 Emerging Infectious Diseases
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MO). Peptides that could not be purified to specifications
within the study period were not evaluated.
MHC Binding Studies
The T2B7 binding assay method (23,24) relies on the
ability of exogenously added peptides to stabilize the class I
MHC/beta 2 microglobulin structure on the surface of trans-
porters associated with antigen processing (TAP)-deficient
cell lines (27,28). Briefly, the HLA B*07 T2 cell line was
prepared for the assay by incubating overnight (16 hours) at
26°C. Before the binding assay, these cells were washed twice
in serum-free media. Solutions of the test peptides at three
concentrations (final concentrations of 10, 20, and 200 µg/mL
in RPMI 1640 (Sigma, St Louis, MO) were plated in triplicate
wells of a 96-well, round-bottom assay plate (Becton Dickinson,
Lincoln Park, NJ). Sixteen wells containing cells without peptide
were included in each plate as background controls.
After 100,000 cells were added to each well, the plates
were incubated for 4 hours at 37°C, 5% CO2, followed by
centrifugation at 110 x g for 10 minutes at 4°C. The
supernatant was discarded, and the remaining cells were
resuspended. One hundred µL of anti-HLA-B*07 primary
antibody-containing hybridoma supernatant was diluted in
staining buffer (1:10 dilution of ME1 supernatant produced
by HB-119 cell line [ATCC, Rockville, MD] in staining buffer:
phosphate-buffered saline [PBS], 5% fetal bovine serum, 0.1%
sodium azide) was added to all the wells. Primary antibody
was incubated with the peptide-pulsed cells for 30 minutes at
4°C. After washing three times with staining buffer, the cells
were resuspended, and 100 µL of a 1:250 dilution of
fluorescein isothiocyanate (FITC)-labeled secondary antibody
(FITC-labeled Goat F[ab']2 anti-mouse IgG [H+L] [Caltag,
Burlingame, CA]) in staining buffer was added to all the
wells. The binding studies are predicated on the assumption
that the primary antibody recognizes an epitope on the HLA
with a configuration that is unchanged by the stabilizing
peptide. The plates were incubated for 30 minutes at 4°C,
then washed three times with staining buffer. The contents of
each well were then resuspended in 200 µL of fixing buffer
(PBS, 1% paraformaldehyde).
The 16 negative control wells in each plate contained no
peptide but did contain cells, primary antibody, and
secondary antibody. An additional set of wells was plated
with peptide at the highest concentration (200 µg/mL), but no
primary antibody was added to the wells as a control for
nonspecific secondary antibody binding. One positive control
peptide (the known B*07 binder) was tested in triplicate at
three concentrations (final concentrations of 10, 20, and 200
µg/mL in RPMI 1640) in each assay plate.
Following fixing, the presence of fluorescent secondary
antibody on the surface of T2 cells (gated to the appropriate
cell size) was measured at 488 nm on a FACScan flow
cytometer (Becton Dickinson). The mean linear fluorescence
of 10,000 events was measured and compared with the
background fluorescence of cells plated in control wells. The
entire assay was repeated 4 times, so that each peptide was
tested in a total of 36 wells (triplicate wells, three
concentrations, four assays).
The B*07 molecule was considered to be stabilized on the
surface of the T2B7 cells if the average of the mean linear
fluorescence for the triplicate wells at each concentration of
peptide was >10% higher than the average of the 16 negative
control wells (and p<0.05 in two-way comparisons by
ANOVA). Binding was rated as strong, moderate, weak, or
none, based on the number of significantly positive wells by
pair-wise ANOVA (Table 3).
Table 3. West Nile virus T2B7 binding assay results
Avg. fold Fluorescence ratio Fluorescence ratio
inc.  Avg. (peptide/negative control) comparisons (p value)
Peptide no. AA sequence EBPa @200b  MFI 10 20 200 control -10 control -20 control -200 Summary
WNB7 0004 AVKDELNTLL 47.77 1.0 842.5 0.91 0.89 0.90 0.021 0.007 0.009 None
WNB7 0005 APAYSFNCLG 47.03 1.2 743.5 0.96 1.09 1.14 0.511 0.127 0.020 Weak
WNB7 0006 AAKKKGASLL 45.3 1.2 708.1 1.01 1.04 1.19 0.717 0.100 0.000 Weak
WNB7 0007 NPMILAAGLI 36.60 1.1 944.6 0.89 0.92 1.00 0.008 0.051 0.949 None
WNB7 0008 IPAGFEPEML 36.02 1.9 1,207.4 1.03 1.18 1.89 0.468 0.000 0.000 Moderate
WNB7 0009 TPAAPSYTLK 35.68 1.5 954.5 1.03 1.13 1.55 0.372 0.001 0.000 Moderate
WNB7 0010 VPCRGQDELV 32.57 1.0 658.6 1.05 1.06 1.04 0.053 0.015 0.118 None
WNB7 0011 GPGHEEPQLV 32.35 1.0 848.9 1.01 1.03 0.98 0.759 0.521 0.689 None
WNB7 0012 AGMLLLSLLL 31.17 -- -- -- -- -- -- -- -- --
WNB7 0013 EPPEGVKYVL 31.07 1.1 681.7 1.08 1.10 1.06 0.004 0.000 0.023 Weak
WNB7 0014 MPAILIALLV 30.23 --  -- -- -- -- -- -- -- --
WNB7 0015 KPTGSASSLV 28.79 1.7 1,070.2 1.04 1.08 1.68 0.243 0.012 0.000 Weak
WNB7 0017 RPRWIDARVY 23.99 1.9 1,714.0 1.18 1.43 1.97 0.003 0.000 0.000 Strong
WNB7 0018 VPGTKIAGML 23.10 1.7 1,088.4 0.98 1.06 1.54 0.533 0.058 0.000 Weak
WNB7 0019 RPQRHDEKTL 22.49 2.8 1,644.6 1.32 1.57 2.77 0.000 0.000 0.000 Strong
WNB7 0020 SPHRVPNYNL 22.40 2.5 1,607.9 1.37 1.59 2.44 0.000 0.000 0.000 Strong
WNB7 0021 IPMTIAGLMF 22.32 -- -- -- -- -- -- -- -- --
WNB7 0023 RPAADGRTVM 20.89 1.5 979.1 1.68 2.01 2.90 0.000 0.000 0.000 Strong
WNB7 0024 TPGLRCLNLD 20.73 1.0 849.6 1.09 1.11 1.01 0.037 0.015 0.821 Weak
WNB7 0025 SVNMTSQVLL 20.09 -- -- -- -- -- -- -- -- --
WNB7 3399 PEDIDCWCTK 0.00 1.1 990.3 0.97 0.96 0.94 0.448 0.396 0.145 None
WNB7 3403 PETPQGLAKI 0.00 1.0 588.9 1.02 1.02 0.99 0.484 0.395 0.716 None
WNB7 3411 PFPESNSPIS 0.00 1.0 626.7 0.90 0.86 0.90 0.020 0.001 0.019 None
WNB7 3415 PRTNTILEDN 0.00 0.9 778.6 0.92 0.91 0.90 0.041 0.020 0.008 None
HIV-1 B7 1291 GPGHKARVLA 28.0 2.2 1,423.8 1.16 1.20 1.72 0.002 0.000 0.000 Strong
1.5 1,370.9 1.12 1.14 1.78 0.000 0.000 0.000 Strong
1.6 1,003.9 0.98 1.06 1.66 0.720 0.195 0.000 Weak
aEBP = estimated binding potential; MFI = mean fluorescence index and T2B7 binding assay results for each of the peptides.
bAverage fold increase in fluorescence of cells incubated with peptide at 200 µg/mL.710 Emerging Infectious Diseases Vol. 7, No. 4, July–August 2001
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Results
The 3,424 decamers derived from the WN virus genome
were evaluated by EpiMatrix B*07 and evaluated for match to
the stored matrix pattern. Most decamers scored for the entire
WN virus genome (by the HLA B*07 scoring matrix) had EBP
scores <1% (Figure 1). Figure 2 shows the distribution of HLA
B*07 scores of a set of 10,000 random peptides (plotted as
their natural logs, to allow better distribution of EBP scores
<1), compared with scores for the set of >300 known HLA B*07
binders and with the scores of the selected WN virus peptides.
The set of peptides selected for study scored well within the
EBP range of the comparison set of >300 known HLA B*07
ligands (Figure 1).
Each peptide in the entire WN virus-NY99 dataset of
peptides was scored by EpiMatrix. Ninety-five of the 3,424
decamers had EBP scores >7%. Of these 95 peptides, 20 of the
25 with EBP scores between 20% and 50% (Table 2a) were
selected for screening. Three peptides with EBP scores >50
(0001, 0002, 0003) were eliminated from the set of peptides
tested because scores in this range are less likely to be B*07
ligands and epitopes (TB/HIV Research Lab and EpiVax,
unpub. data). The amino acid sequence of peptide 0012
overlapped substantially with the human genome, and for
that reason this peptide was also excluded. Three of the
original 25 peptides (0014, 0021, 0025) could not be
synthesized to sufficient purity within the study timeframe.
Two peptides with EBP scores between 50 and 20 (0016 and
0022) were also not tested because they did not fall within a
region of the WN virus genome belonging to a mature WN
virus protein, based on information in the GenBank database.
Sixteen WN virus peptides remained in the final selection.
The final set of 16 WN virus peptides included two from
NS-1, four from NS-2A, five from NS-3, one from NS-4A, five
from NS-5, one from env gp E, and one from prM (Table 2a). In
addition to these peptides, four predicted nonbinder peptides
and a known binder (1291) were also synthesized. Twenty-one
peptides were tested in vitro in T2B7 binding assays.
Binding Results
Triplicate wells of peptide at 10, 20, and 200 µg/mL were
evaluated in each of the T2 B7 binding assays. Table 3
provides information on the mean fluorescence index for the
peptide at 200 µg/mL; the average fold increase over
background for the peptide at 10, 20 and 200 µg/mL; and the
ANOVA analysis for each pairwise comparison (between
fluorescence for cells incubated with one of the concentrations
of the study peptide and the fluorescence of the cells in control
wells).
Twelve of the 16 study peptides demonstrated consistent
binding in the four replicate assays. Of these peptides, four
(0017, 0019, 0020, and 0023) stabilized HLA B*07 on the
surface of T2B7 cells substantially more often than controls in
the four replicate assays (strong binders, Table 3). Two WN
virus peptides (0008, 0009) stabilized HLA B*07 to a
moderate degree. Six WN virus peptides (0005, 0006, 0013,
0015, 0018, and 0024) were weak binders, and four did not bind.
The positive control peptide, 1291, was tested with each
set of peptides. The peptide bound significantly over
background (based on ANOVA) in all three assays. Four
negative control peptides selected for low EBP scores (3399,
3404, 3411, and 3415, all with scores of 0.0%) did not stabilize
T2B7 to a significant degree.
Cross Strain Analysis Results
Peptide 0019, a strong binder, was conserved in all
strains of WN virus (100% or 10 of 10 amino acids) and Kunjin
virus; it was 80% conserved in JE virus strains (8 of 10 amino
acids). Peptides 0017 and 0023, two strong binders, were
100% conserved in all strains of WN virus and Kunjin virus,
80% conserved in JE virus and Murray Valley encephalitis
(MVE) virus, and 90% conserved in some strains of dengue.
Peptide 0020, the fourth strong binder, was conserved in West
Nile and Kunjin (100%), JE virus, MVE virus, and dengue (90%).
The two moderate binders 0008 and 0009 were unique.
Peptide 0008 was 100% conserved in West Nile virus strains,
different by one amino acid from Kunjin virus (closely related
to WN virus), and not conserved in any other flaviviruses.
Peptide 0009 was conserved only in WN virus and Kunjin
virus (100%) and not conserved in any other related flavivirus
strains.
Of the weaker binding peptides (0005, 0006, 0013, 0015,
0018, and 0024), 0005 was 100% conserved across WN,
Kunjin, SLE, and Sindbis viruses. Peptide 0006 was 90%-
100% conserved in WN, Kunjin, JE, and MVE viruses.
Peptide 0013, likewise, was conserved in WN and Kunjin but
less well in JE virus (80%). WN virus 0015 was conserved in
WN virus, Kunjin (100%), JE virus (90%), MVE virus (80%),
SLE virus (90%), and dengue (80%). WN virus 0018 was
conserved in WN virus, JE virus (90%), MVE virus (80%), and
SLE virus (90%). In contrast, peptide 0024 was 100%
conserved in all strains of WN virus (100%, or 10 of 10 amino
acids) and Kunjin virus but not conserved in any other virus of
the flavivirus group.
Estimated Cost
The 3,329 peptides with EBP scores <7% (3,424 to 95)
were considered unlikely to bind to HLA B*07. The EpiMatrix
approach reduced the number of candidate peptides by 97%
(3,329/3,424). Some researchers have adopted a standard
overlapping (OL) approach (constructing a set of 10 amino
acid-long peptides overlapping by 5 amino acids covering the
entire genome [29]). This strategy (10/5 OL set) would have
required the synthesis of 685 decamer peptides for the WN
virus genome, more than 7 times the number (95) selected by
the EpiMatrix approach.
The cost of synthesizing the 16 putative ligands and four
controls (at a cost of $250 per peptide) for this project was
$5,000. Synthesizing the entire selected set and four controls
would have cost $24,750. Had the standard overlapping
peptide approach been used, the cost of synthesizing OL
peptides would have been approximately $170,000 ($250 for
each of 685 peptides). The cost of synthesizing and mapping
the complete overlapping set of peptides representing
decamer peptides overlapping by 9 amino acids (3,423
peptides) would be $856,000 (Table 4).
If the WN virus B7 peptides behave as observed in
previous studies of HLA B*07 peptide datasets (23; De Groot
et al., unpub. data), additional HLA-B7 ligands would be
identified (approximately 76%; 72 of the set of 95 WN virus
peptides with EBP scores >7). If, by performing more
overlapping peptide assays, this larger set of 72 (putative)
ligands had been found, the cost per ligand with the OL
approach would have been approximately $3,600 per ligand,
compared with $617 per ligand for 72 ligands with the
EpiMatrix approach. If no epitopes were to be missed, the711 Vol. 7, No. 4, July–August 2001 Emerging Infectious Diseases
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exhaustive approach could be used at an estimated cost of
$18,000 per ligand. This approach would have cost
approximately five times more than the OL approach and 30
times more than the EpiMatrix approach.
Time Required for Analysis
Analysis of the WN virus genome and selection of the WN
virus peptides was performed during one working week.
Selected peptides were obtained in batches over a 4-week
period. T2B7 binding assays were performed as the peptides
arrived. Overall, the T2 B7 binding assays and data analysis
took place over 20 working days, and the entire process from
peptide selection to completion of data analysis took 8 weeks.
Eliminating delays associated with peptide synthesis would
have reduced the time required to 4 weeks.
Discussion
Using the EpiMatrix approach, we rapidly identified four
excellent B*07-restricted T-cell epitope candidates for WN
virus. Overall, 12 (75%) of 16 selected peptides bound in T2B7
binding assays. These binding results compare favorably with
those of other T2B7 binding results for HIV-1 (16,23). Xia Jin
et al. tested 29 HIV-1 peptides with EBP scores of 7%, of which
10 (35%) bound to T2B7 cells in vitro and 4 (14%) were
subsequently demonstrated to be HLA-B7 restricted CTL
epitopes in assays performed with CD8+ T-cell lines derived
from an HIV-infected patient (23). In a separate study (16) of
HLA B*07-restricted peptides, 25 peptides were tested,
including a known HLA B*07-restricted epitope (peptide
1291, also used in this study). Nineteen (76%) of 25 peptides
were shown to bind to T2B7 cells in vitro, and 60% of the
peptides stimulated gamma-interferon release in T-cell
assays performed with HIV-1-infected patients’ cells.
Based on these experiences with EpiMatrix HLA-B7
selection, additional peptides from the original list of 95 WN
virus peptides (EBP scores >7) might be expected to bind to
HLA B*07 and stimulate T-cell responses. If the rest of the
WN virus B7 peptides behave as observed in the HIV-1
datasets, 21 to 60 additional HLA-B7 ligands might be
identified (76%, or 72 of the set of 95 WN virus peptides with
EBP scores >7). This observation is also consistent with
estimates of the number of epitopes in a given protein (30).
Even at this higher number of total ligands, the cost per
ligand of the OL approach would still have been more
expensive than the EpiMatrix approach. Furthermore, the
exhaustive approach would have cost approximately five
times more than the OL (10/5) approach and 30 times more
than the EpiMatrix approach. The EpiMatrix approach would
also be substantially more rapid than OL or exhaustive
testing of overlapping peptides.
EpiMatrix is one of several epitope mapping tools
available to researchers, including the tool available at the
SYFPEITHI (31) website and the HLA binding prediction tool
available on the National Institutes of Health (BIMAS) site
(32). Neither of these sites returned exactly the same
predictions as EpiMatrix for the WN virus genome; however,
no direct comparison was made. Either of these web-based
epitope-mapping tools could also accelerate the process of
epitope mapping the WN virus genome by the approach
described here.
The matrix-based approach used by EpiMatrix develop-
ers occasionally results in the selection of peptides that do not
fit standard anchor-based and extended anchor motifs such as
those available on the SYFPEITHI website. As a result, WN
virus peptides selected by the EpiMatrix method and included
in this study did not always fit the conventional, anchor-based
format of proline in position 2 and leucine or phenylalanine in
position 9 (17). For example, the sequence of one weak WN
virus binder, AAKKKGASLL, has little in common with
published HLA B*07 motifs, illustrating how EpiMatrix is
able to prospectively identify ligands that do not necessarily
match anchor-based motifs.
Although EpiMatrix appears to provide excellent
discrimination between most published HLA B*07 ligands
and a set of random peptides (Figure 2), there is still overlap
between the lower-scoring published HLA B*07 ligands and
the scores of some of the random peptides. Since the universe
of HLA B*07 ligands is unknown, some of the set of random
peptides could be previously unidentified HLA B*07 ligands.
Furthermore, EpiMatrix scored several known HLA B*07
ligands very low, reflecting either inaccuracy of the HLA B*07
matrix or inaccurate reporting of these ligands. Further study
of these low-scoring HLA B*07 ligands may improve
knowledge of the rules determining HLA B*07 binding.
Epitopes that are specific for WN virus could be used to
develop diagnostic tests such as tetramer assays for WN virus
(17). The tetramer staining assay relies only on the
interaction between the tetramer reagent and T-cell receptors
on the surface of T cells; it can be performed in <30 minutes on
as little as 2 mL of blood. Peptide 0008 was unique to WN
virus, with only 8 of 10 amino acids in this sequence conserved
in Kunjin virus; the sequence was even less well conserved in
other members of the flavivirus family. Peptide 0009 would
also be a strong candidate reagent for a diagnostic test, as it
was conserved in Kunjin and in many strains of WN virus but
not in any other member of the flavivirus family.
The incubation period in humans (i.e., time from infection
to onset of disease symptoms) for WN virus encephalitis is
Table 4. Projected cost of HLA-B7 epitope mapping for the West Nile
virus genome
Overlapping  Complete
  (OL)a     OL set
 (10 AA  (decamers
long OL by overlapping
EpiMatrix by 5 AA)     by 9)
Peptides 20 685 3,424
Peptide synthesis $5,000 $171,250 $856,000
Time (days) 28 959 4,794
Technician/reagent cost $2,608 $89,332 $446,527
Cost (synthesis + assay) $634 $21,715 $108,544
  12 ligandsb
Cost (synthesis + assay) $617 $3,619 $18,091
  72 ligandsc
aThe standard overlapping approach, constructing a set of 10 amino-acid long
peptides overlapping by 5 amino acids (10/5 OL set) would require the synthesis
of 685 decamer peptides, approximately 30 times the number synthesized and
tested by the EpiMatrix approach. The “discovery” cost per ligand was
calculated by dividing the total cost of synthesis and screening for each of the
approaches by the number of ligands expected to be discovered (12 ligands, a
low estimate, and 72 ligands, a high estimate).
bBased on the assumption that only 12 ligands will be found
cBased on the assumption that as many as 72 ligands may be found. In that
case, 95 peptides would be synthesized for EpiMatrix, 685 for OL (10 by 5), and
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usually 5 to 15 days. Antibodies are detectable within 3 to 7
days; however, to confirm infection, antibody assays must be
repeated in the acute and convalescent phases. In contrast,
recent tetramer-staining studies (33) indicate that cell
responses may be detectable 2 to 3 days after acute infection.
The initial CTL response to acute infection with a virus, as
measured by tetramer technology, can be dramatic. For
example, during the acute immune response to lymphocytic
choriomeningitis virus (LCMV) in BALB/c mice, 55% of all
CD8+ splenocytes are stained with an LCMV-specific
tetramer (34). The method is extremely robust and can detect
antigen-specific populations at frequencies as low as 1:5,000
CD8+ T cells, or approximately 1:50,000 peripheral blood
mononuclear cells (35). Results of the studies performed here
suggest that peptides 0008 and 0009, which are relatively
specific for WN virus and which score in the range of
EpiMatrix scores shown to be compatible with immunogenic-
ity (24), would be reasonable first candidates for the
development of a tetramer-based diagnostic reagent for WN
virus.
No specific vaccine or antiviral treatment exists for WN
virus infection. CTL response will likely be one critical
component of the immune response against WN virus.
Development of a preventive or therapeutic vaccine against
this public health threat would be greatly expedited if the
correlates of immune response were determined and
appropriate components rapidly incorporated into a vaccine.
Epitopes defined by methods such as the one described here
are likely to contribute substantially to the development of
new research and diagnostic reagents and vaccines for WN
virus and other emerging infectious diseases.
Dr. De Groot is director of the TB/HIV Research Laboratory and
assistant professor of community health and medicine at Brown Uni-
versity. She is also CEO and President of EpiVax, Inc., a privately owned
bioinformatics and vaccine design company in Providence, RI. She trained
in informatics and immunology at the National Institutes of Health and
is an HIV/AIDS specialist in correctional settings.
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